Cargando…
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
OBJECTIVE: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. METHODS: We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252519/ https://www.ncbi.nlm.nih.gov/pubmed/33938021 http://dx.doi.org/10.1002/ana.26094 |
_version_ | 1783717318009815040 |
---|---|
author | Lai, Dongbing Alipanahi, Babak Fontanillas, Pierre Schwantes‐An, Tae‐Hwi Aasly, Jan Alcalay, Roy N. Beecham, Gary W. Berg, Daniela Bressman, Susan Brice, Alexis Brockman, Kathrin Clark, Lorraine Cookson, Mark Das, Sayantan Van Deerlin, Vivianna Follett, Jordan Farrer, Matthew J. Trinh, Joanne Gasser, Thomas Goldwurm, Stefano Gustavsson, Emil Klein, Christine Lang, Anthony E. Langston, J. William Latourelle, Jeanne Lynch, Timothy Marder, Karen Marras, Connie Martin, Eden R. McLean, Cory Y. Mejia‐Santana, Helen Molho, Eric Myers, Richard H. Nuytemans, Karen Ozelius, Laurie Payami, Haydeh Raymond, Deborah Rogaeva, Ekaterina Rogers, Michael P. Ross, Owen A. Samii, Ali Saunders‐Pullman, Rachel Schüle, Birgitt Schulte, Claudia Scott, William K. Tanner, Caroline Tolosa, Eduardo Tomkins, James E. Vilas, Dolores Trojanowski, John Q. Uitti, Ryan Vance, Jeffery M. Visanji, Naomi P. Wszolek, Zbigniew K. Zabetian, Cyrus P. Mirelman, Anat Giladi, Nir Orr Urtreger, Avi Cannon, Paul Fiske, Brian Foroud, Tatiana |
author_facet | Lai, Dongbing Alipanahi, Babak Fontanillas, Pierre Schwantes‐An, Tae‐Hwi Aasly, Jan Alcalay, Roy N. Beecham, Gary W. Berg, Daniela Bressman, Susan Brice, Alexis Brockman, Kathrin Clark, Lorraine Cookson, Mark Das, Sayantan Van Deerlin, Vivianna Follett, Jordan Farrer, Matthew J. Trinh, Joanne Gasser, Thomas Goldwurm, Stefano Gustavsson, Emil Klein, Christine Lang, Anthony E. Langston, J. William Latourelle, Jeanne Lynch, Timothy Marder, Karen Marras, Connie Martin, Eden R. McLean, Cory Y. Mejia‐Santana, Helen Molho, Eric Myers, Richard H. Nuytemans, Karen Ozelius, Laurie Payami, Haydeh Raymond, Deborah Rogaeva, Ekaterina Rogers, Michael P. Ross, Owen A. Samii, Ali Saunders‐Pullman, Rachel Schüle, Birgitt Schulte, Claudia Scott, William K. Tanner, Caroline Tolosa, Eduardo Tomkins, James E. Vilas, Dolores Trojanowski, John Q. Uitti, Ryan Vance, Jeffery M. Visanji, Naomi P. Wszolek, Zbigniew K. Zabetian, Cyrus P. Mirelman, Anat Giladi, Nir Orr Urtreger, Avi Cannon, Paul Fiske, Brian Foroud, Tatiana |
author_sort | Lai, Dongbing |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. METHODS: We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. RESULTS: A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. INTERPRETATION: This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94 |
format | Online Article Text |
id | pubmed-8252519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82525192021-07-09 Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease Lai, Dongbing Alipanahi, Babak Fontanillas, Pierre Schwantes‐An, Tae‐Hwi Aasly, Jan Alcalay, Roy N. Beecham, Gary W. Berg, Daniela Bressman, Susan Brice, Alexis Brockman, Kathrin Clark, Lorraine Cookson, Mark Das, Sayantan Van Deerlin, Vivianna Follett, Jordan Farrer, Matthew J. Trinh, Joanne Gasser, Thomas Goldwurm, Stefano Gustavsson, Emil Klein, Christine Lang, Anthony E. Langston, J. William Latourelle, Jeanne Lynch, Timothy Marder, Karen Marras, Connie Martin, Eden R. McLean, Cory Y. Mejia‐Santana, Helen Molho, Eric Myers, Richard H. Nuytemans, Karen Ozelius, Laurie Payami, Haydeh Raymond, Deborah Rogaeva, Ekaterina Rogers, Michael P. Ross, Owen A. Samii, Ali Saunders‐Pullman, Rachel Schüle, Birgitt Schulte, Claudia Scott, William K. Tanner, Caroline Tolosa, Eduardo Tomkins, James E. Vilas, Dolores Trojanowski, John Q. Uitti, Ryan Vance, Jeffery M. Visanji, Naomi P. Wszolek, Zbigniew K. Zabetian, Cyrus P. Mirelman, Anat Giladi, Nir Orr Urtreger, Avi Cannon, Paul Fiske, Brian Foroud, Tatiana Ann Neurol Research Articles OBJECTIVE: The aim of this study was to search for genes/variants that modify the effect of LRRK2 mutations in terms of penetrance and age‐at‐onset of Parkinson's disease. METHODS: We performed the first genomewide association study of penetrance and age‐at‐onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non‐cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age‐at‐onset of LRRK2 mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age‐at‐onset in LRRK2 mutation carriers. RESULTS: A variant located in the intronic region of CORO1C on chromosome 12 (rs77395454; p value = 2.5E‐08, beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co‐immunoprecipitation analyses of LRRK2 and CORO1C supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant: p value = 1.1E‐07; age‐at‐onset top variant: p value = 9.3E‐07). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age‐at‐onset. INTERPRETATION: This study suggests that variants within or near CORO1C may modify the penetrance of LRRK2 mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of LRRK2 mutations. ANN NEUROL 2021;90:82–94 John Wiley & Sons, Inc. 2021-05-17 2021-07 /pmc/articles/PMC8252519/ /pubmed/33938021 http://dx.doi.org/10.1002/ana.26094 Text en © 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Research Articles Lai, Dongbing Alipanahi, Babak Fontanillas, Pierre Schwantes‐An, Tae‐Hwi Aasly, Jan Alcalay, Roy N. Beecham, Gary W. Berg, Daniela Bressman, Susan Brice, Alexis Brockman, Kathrin Clark, Lorraine Cookson, Mark Das, Sayantan Van Deerlin, Vivianna Follett, Jordan Farrer, Matthew J. Trinh, Joanne Gasser, Thomas Goldwurm, Stefano Gustavsson, Emil Klein, Christine Lang, Anthony E. Langston, J. William Latourelle, Jeanne Lynch, Timothy Marder, Karen Marras, Connie Martin, Eden R. McLean, Cory Y. Mejia‐Santana, Helen Molho, Eric Myers, Richard H. Nuytemans, Karen Ozelius, Laurie Payami, Haydeh Raymond, Deborah Rogaeva, Ekaterina Rogers, Michael P. Ross, Owen A. Samii, Ali Saunders‐Pullman, Rachel Schüle, Birgitt Schulte, Claudia Scott, William K. Tanner, Caroline Tolosa, Eduardo Tomkins, James E. Vilas, Dolores Trojanowski, John Q. Uitti, Ryan Vance, Jeffery M. Visanji, Naomi P. Wszolek, Zbigniew K. Zabetian, Cyrus P. Mirelman, Anat Giladi, Nir Orr Urtreger, Avi Cannon, Paul Fiske, Brian Foroud, Tatiana Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title | Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title_full | Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title_fullStr | Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title_full_unstemmed | Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title_short | Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease |
title_sort | genomewide association studies of lrrk2 modifiers of parkinson's disease |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252519/ https://www.ncbi.nlm.nih.gov/pubmed/33938021 http://dx.doi.org/10.1002/ana.26094 |
work_keys_str_mv | AT laidongbing genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT alipanahibabak genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT fontanillaspierre genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT schwantesantaehwi genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT aaslyjan genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT alcalayroyn genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT beechamgaryw genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT bergdaniela genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT bressmansusan genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT bricealexis genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT brockmankathrin genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT clarklorraine genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT cooksonmark genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT dassayantan genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT vandeerlinvivianna genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT follettjordan genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT farrermatthewj genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT trinhjoanne genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT gasserthomas genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT goldwurmstefano genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT gustavssonemil genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT kleinchristine genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT langanthonye genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT langstonjwilliam genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT latourellejeanne genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT lynchtimothy genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT marderkaren genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT marrasconnie genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT martinedenr genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT mcleancoryy genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT mejiasantanahelen genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT molhoeric genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT myersrichardh genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT nuytemanskaren genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT ozeliuslaurie genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT payamihaydeh genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT raymonddeborah genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT rogaevaekaterina genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT rogersmichaelp genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT rossowena genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT samiiali genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT saunderspullmanrachel genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT schulebirgitt genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT schulteclaudia genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT scottwilliamk genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT tannercaroline genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT tolosaeduardo genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT tomkinsjamese genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT vilasdolores genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT trojanowskijohnq genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT uittiryan genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT vancejefferym genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT visanjinaomip genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT wszolekzbigniewk genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT zabetiancyrusp genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT mirelmananat genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT giladinir genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT orrurtregeravi genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT cannonpaul genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT fiskebrian genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease AT foroudtatiana genomewideassociationstudiesoflrrk2modifiersofparkinsonsdisease |